FRT
55
2
ABT
44
-3
NTRS
52
-3
ISRG
50
-4
DAL
74
-2
PPG
54
-4
A
62
-2
CMCSA
42
-3
TSCO
72
-3
PAYX
33
-3
KSS
36
-3
V
38
-6
GLW
44
-4
MLM
58
-2
RHI
28
-2
M
24
-3
K
41
-4
EFX
49
-6
MS
62
-3
DRI
45
-3
FRT
55
2
ABT
44
-3
NTRS
52
-3
ISRG
50
-4
DAL
74
-2
PPG
54
-4
A
62
-2
CMCSA
42
-3
TSCO
72
-3
PAYX
33
-3
KSS
36
-3
V
38
-6
GLW
44
-4
MLM
58
-2
RHI
28
-2
M
24
-3
K
41
-4
EFX
49
-6
MS
62
-3
DRI
45
-3
Financhill
Back

Arcutis Biotherapeutics 10K Form

Buy
66

ARQT
Arcutis Biotherapeutics

Last Price:
$15.01
Seasonality Move:
-23.58%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ARQT News And Ratings

See the #1 stock for the next 7 days that we like better than ARQT

ARQT Financial Statistics

Sales & Book Value

Annual Sales: $196.5M
Cash Flow: $-31M
Price / Cash Flow: 0
Annual Sales: $1.20
Price / Book: 12.54

Profitability

EPS (TTM): -1.04000
Net Income (TTM): $-129.7M
Gross Margin: $177.4M
Return on Equity: -74.7%
Return on Assets: -31.58%

Arcutis Biotherapeutics Earnings Forecast

Key Arcutis Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for ARQT is 90.27%.
  • The Selling, General & Administrative Expenses for ARQT have been equal to 116.71% of Gross Profit Margin.
  • The Research & Development expenses have been 38.88% of Revenue.
  • The Net Earning history of ARQT is -71.25% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

Arcutis Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ARQT
CUSIP: 03969K
Website: arcutis.com

Debt

Debt-to-Equity Ratio: 0.75
Current Ratio: 3.55
Quick Ratio: 3.11

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 87.44

ARQT Technical Analysis vs Fundamental Analysis

Buy
66
Arcutis Biotherapeutics (ARQT) is a Buy

Is Arcutis Biotherapeutics a Buy or a Sell?